Caldevilla RY, Bacallao MRA, Gutiérrez GF, Mañalich CR, Dávalos IJM

Language: Spanish
References: 34
Page: 1-13
PDF size: 282.37 Kb.

ABSTRACT

Introduction: Urolithiasis has increased in recent decades. Autosomal dominant polycystic kidney disease (ADPKD), the most common of all hereditary kidney diseases, occupies a predominant position in terms of incidence.
Objectives: Identify the frequency of occurrence of urinary metabolic disorders in Cuban urolithiasis patients with and without ADPKD.
Methods: A descriptive cross-sectional study was conducted of 579 adult patients without ADPKD selected by simple random sampling, and 21 patients with ADPKD, from the total urolithiasis patients undergoing renal metabolic evaluation at the Renal Physiopathology Laboratory of the Institute of Nephrology in the period 2010-2015. Data were obtained from medical records and reports of renal metabolic studies. Information was processed with the statistical software SPSS version 22.0. Average and standard deviation were estimated and use was made of frequency distribution analysis and homogeneity testing.
Results: A predominance was found of female sex among patients with ADPKD (57.1%) and male sex among patients without ADPKD (63.4%). The most common disorders were hypercalciuria (45.3%) and hypophosphatemia (17.1%) in the non-polycystic population, and increased uric acid clearance (38.1%) and hypercalciuria (23.8%) in polycystic patients. Statistically significant differences were found in uric acid clearance increase (p = 0.01) and hyperphosphatemia (p = 0.04).
Conclusions: The main metabolic disorders of lithiasis patients, polycystic as well as non-polycystic, are increased uric acid clearance, hypercalciuria, hyperuricosuria and hypophosphatemia, with a varying order of presentation. Increased uric acid clearance and hyperphosphatemia are more common in polycystic lithiasis patients.

REFERENCES

1. Raheem OA, Khandwala YS, Sur RL, Ghani KR, Denstedt JD. Burden of Urolithiasis: Trends in Prevalence, Treatments, and Costs. Eur Urol Focus. 2017;3(1):18-26.

2. Ziemba JB, Matlaga BR. Epidemiology and economics of nephrolithiasis. Investig Clin Urol. 2017;58(5):299-306.

3. Ferraro PM, Curhan GC, D'Addessi A, Gambaro G. Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. J Nephrol. 2017;30(2):227-33.

4. Sorokin I, Pearle MS. Medical therapy for nephrolithiasis: State of the art. Asian J Urol. 2018; 5(4):243-55.

5. Mallet A, Tunnicliffe D. Management of Renal Stone Disease. KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline. Introduction to the KHA-CARI Guidelines on ADPKD. Semin Nephrol 2015;35:521-3.

6. Pak CY, Poindexter JR, Adams-Huet B, Pearle MS. Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med. 2003;115:26-32.

7. Skolarikos A, Straub M, Knoll T, Sarica K, Seitz C, Petřík A, et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. Eur Urol. 2015;67(4):750-63.

8. Sommerer C, Zeier M. Clinical manifestation and management of ADPKD in Western Countries. Kidney Dis (Basel). 2016;2(3):120-27.

9. Tiselius HG, Daudon M, Thomas K, Seitz C. Metabolic Work-up of Patients with Urolithiasis: Indications and Diagnostic Algorithm. Eur Urol Focus. 2017;3(1):62-71.

10. Dubois D, Dubois E. F. A formula to estimate the approximate surface area if height and weight be known. Arch. Intern.Med. 1916;17:862-5.

11. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, Kurella Tamura M, Feldman HI. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014 May; 63(5):713-35.

12. Ramello A, Vitale C, Marangella M. Epidemiology of nephrolithiasis. J Nephrol 2000; 13(3):S45-S50.

13. Bacallao Méndez RA, Victores Aguiar I, Mañalich Comas R, Gutiérrez García F, Llerena Ferrer B, Almaguer López MM. Caracterización clínico epidemiológica de la litiasis urinaria en un área rural de Artemisa. Rev Cubana Invest Bioméd. 2016;35(4):300-10.

14. Finlayson B. Symposium on renal lithiasis in review. Urol Clin North Am 1974;1:181-212.

15. Bae SR, Seong JM, Kim LY, Paick SH, Kim HG, Lho YS, et al. The epidemiology of reno-ureteral stone disease in Koreans: a nationwide population-based study. Urolithiasis. Apr 2014;42(2):109-14.

16. Bacallao Méndez RA, Madrid Mancia C, Mañalich Comas R, Gutiérrez García F, Badell Moore A. Trastornos metabólicos renales en pacientes cubanos adultos con litiasis urinarias. Rev Cubana Med 2014;53(4):456-67.

17. Idrizi A, Barbullushi M, Gjata M, Roshi E, Backa T, Kodra S. Prevalence of nephrolithiasis in polycystic kidney disease. Central European Journal of Medicine 2011;6(4):497-51.

18. Alam A. Risk factors for progression in ADPKD. Curr Opin Nephrol Hypertens. 2015;24(3):290-4.

19. Torres VE, Erickson SB, Smith LH. The association of nephrolithiasis and autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1988;11(4):318-25.

20. Grampsas SA, Chandhoke PS, Fan J, Glass MA, Townsend R, Jonhson AM, et al. Anatomic and metabolic risks factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;36(1):53-7.

21. Torres VE, Wilson DM, Hattery RR, Segura JW. Renal stone disease in autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1993;22(4):513-9.

22. Kathleen A, Barry MD. Citrate Salts for Preventing and Treating Calcium-Containing Kidney Stones in Adults. Am Fam Physician. 2017;95(9):552-3.

23. Sakhaee K, Moe OW. Urolithiasis. En: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL, Editores. The Kidney. 10 ed. Philadelphia: Elsevier Health Sciences; 2016, pp. 1322-67.

24. Pak CYC. Medical prevention of renal stone disease. Nephron 1999;81(1):60-5.

25. Coe FL, Parks JH, Moore ES. Familial idiopathic hypercalciuria. N Engl J Med. 1979;300(7):337-40.

26. Nishiura JL, Neves R, Heilberg IP. Evaluation of Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease Patients. Clin J Am Soc Nephrol. 2009;4(4):838-44.

27. Lorenzo-Sellares V, Torres-Ramírez A. Primary hyperoxaluria. Nefrología. 2014;34(3):273-424.

28. Levy FL, Adams-Huet B, Pak CYC. Ambulatory evaluation of nephrolithiasis an update of a 1980 protocolaboradores Am J Med. 1995;98:50-9.

29. Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: New insights after 14 years of follow up. J Am Soc Nephrol. 2004;15:3225-32.

30. Curhan GC, Willet WC, Knight EL, Stampfer MJ. Dietary factors and the risk of incident kidney stones in younger women: Nurses’ Health Study II. Arch Intern Med. 2004;164:885-91.

31. Xu C, Zhang C, Wang XL, et al. Self-Fluid Management in Prevention of Kidney Stones: A PRISMA-Compliant Systematic Review and Dose-Response Meta-Analysis of Observational Studies. Medicine (Baltimore). 2015;94(27):e1042. DOI: 10.1097/MD.0000000000001042.

32. Cheungpasitporn W, Rossetti S, Treatment effect, adherence, and safety of high fluid intake for the prevention of incident and recurrent kidney stones: a systematic review and meta-analysis.J Nephrol. 2016;29(2):211-9.

33. Bacallao Méndez R, Caldevilla Rodríguez Y, Mañalich Comas R, Gutiérrez García F, Badell Moore A, Llerena Ferrer B. Efecto de la ingestión de sal en la excreción renal de agua en pacientes urolitiásicos. Rev Cubana Invest Bioméd. 2016;35(4):323-30.

34. Vikrant S, Parashar A. Autosomal dominant polycystic kidney disease: Study of clinical characteristics in an Indian population. Saudi Journal of Kidney Diseases and Transplantation. 2017;28:115-124.